These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 30054160)

  • 1. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
    Odusanya OO; Kuyinu YA; Kehinde OA; Francois N; Yarzabal JP; Moreira M; Borys D; Schuerman L
    Niger Postgrad Med J; 2013 Dec; 20(4):272-81. PubMed ID: 24633268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
    Huu TN; Toan NT; Tuan HM; Viet HL; Le Thanh Binh P; Yu TW; Shafi F; Habib A; Borys D
    BMC Infect Dis; 2013 Feb; 13():95. PubMed ID: 23432812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable
    Horn M; Behre U; Traskine M; Dobbelaere K; Borys D
    Hum Vaccin Immunother; 2021 May; 17(5):1463-1469. PubMed ID: 33175600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
    Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
    Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.